WallStSmart
GILD

Gilead Sciences Inc

NASDAQ: GILD · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$130.84
+1.55% today

Updated 2026-04-29

Market cap
$161.85B
P/E ratio
19.23
P/S ratio
5.50x
EPS (TTM)
$6.78
Dividend yield
2.36%
52W range
$93 – $156
Volume
6.1M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Gilead Sciences Inc (GILD) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$130.84
Consensus
$146.50
+11.97%
2030 Target
$377.22
+188.31%
DCF
$237.26
+45.70% MoS
18 analysts:
8 Buy3 Hold0 Sell

Management guidance

No specific revenue guidance from CEO Daniel O'Day found in provided materials. Company has historically provided annual guidance near earnings announcements. Most recent analyst consensus estimates $30.81B revenue for 2026 and $32.65B for 2027, with 4.65% and 5.96% growth rates respectively.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$642.67
$39.9B Rev × 20x P/S
Base case (2030)
$377.22
$39.9B Rev × 12x P/S
Bear case (2030)
$251.48
$39.9B Rev × 8x P/S

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)2030 (E)
Revenue$27.1B$28.8B$29.4B$30.8B$32.6B$34.7B$37.1B$39.9B
Revenue growth—6.0%2.4%4.7%6.0%6.3%7.0%7.3%
EPS$7.04$4.61$8.15$8.84$9.82$10.78$11.89$13.15
P/S ratio———12.0x12.0x12.0x12.0x12.0x
Implied price———$293.39$307.36$335.30$363.25$377.22

Catalysts & risks

Growth catalysts
+ Arcellx acquisition ($7.8B) integration and anitocabtagene autoleucel (anito-cel) cell therapy commercialization driving oncology revenue growth
+ Ouro Medicines acquisition ($2.175B) advancing gamgertamig T cell engager for autoimmune/inflammatory diseases - 'immune reset' market opportunity
+ HIV pipeline expansion with single-tablet regimens and Lenacapavir-based combinations maintaining market leadership in prevention and treatment
+ Yeztugo and other oncology product expansion supporting higher-margin portfolio shift
+ Potential $5B anito-cel CVR payoff if sales reach $6B by end of 2029
Key risks
- Patent cliff risk on core HIV antivirals after 2027-2028; generic competition pressure on legacy franchise
- Execution risk on two major acquisitions (Arcellx, Ouro) requiring successful integration and clinical/commercial success
- Cell therapy manufacturing and supply chain complexity; clinical trial failures or delayed approvals on key assets
- Competitive pressures from Merck HIV programs and broader oncology/immunology competition
- Regulatory/pricing pressure particularly from U.S. government and payers on high-cost cell therapies

Methodology

Gilead Sciences Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 18 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 6, 2026.